After receiving a weekly dose of the treatment for 68 weeks , study participants, led by the Obesity Research Center at University College London, lost an average of 15.3 kilograms, and 35% lost more than one kilogram. fifth of your body weight.
The study involved 1,961 people from 16 countries in Europe, Asia, North America and South America, with an average body weight of 105 kilograms. Participants received 2.4 milligrams of this drug once weekly , administered by subcutaneous injection. None of the participants was diabetic.
“The findings of this study represent a breakthrough in improving the health of people with obesity,” says Rachel Batterham, study leader in the New England Journal of Medicine . “No other drug has come close to producing this level of weight loss ; this really is a game changer. For the first time, people can achieve through medication what was only possible through surgery. “
In addition to experiencing an average decrease in body mass index of 5.54, the participants also showed reduced risk of heart disease and diabetes, waist circumference, blood sugar, blood fat, and blood pressure.
Therefore, semaglutide has already been submitted for approval as an obesity treatment to drug regulatory authorities in Great Britain, Europe and North America.
Reference: Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP 1 Study Group February 10, 2021 The New England Journal of Medicine DOI: 10.1056 / NEJMoa2032183
